Zeitschriftenartikel zum Thema „Immune-related adverse effect“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Immune-related adverse effect" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Bangalore Kumar, Anagha, Alan Bryce, Prakash Vishnu, Svetomir Markovic und Marian McEvoy. „Associations of Cutaneous Immune-Related Adverse Effects of Immunotherapy With Treatment Response in Patients With Metastatic Melanoma“. SKIN The Journal of Cutaneous Medicine 5, Nr. 2 (06.03.2021): 108–17. http://dx.doi.org/10.25251/skin.5.2.5.
Der volle Inhalt der QuelleWilliams, Kiersten J., Dennis W. Grauer, David W. Henry und Michelle L. Rockey. „Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors“. Journal of Oncology Pharmacy Practice 25, Nr. 3 (09.12.2017): 544–50. http://dx.doi.org/10.1177/1078155217744872.
Der volle Inhalt der QuelleMuir, Christopher A., Roderick J. Clifton-Bligh, Georgina V. Long, Richard A. Scolyer, Serigne N. Lo, Matteo S. Carlino, Venessa H. M. Tsang und Alexander M. Menzies. „Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment“. Journal of Clinical Endocrinology & Metabolism 106, Nr. 9 (20.04.2021): e3704-e3713. http://dx.doi.org/10.1210/clinem/dgab263.
Der volle Inhalt der QuelleBansal, Aditi, Ankur Singla, Davinder Paul und Sukhjot Kaur. „Pembrolizumab-induced lichen planus: A rare immune-related adverse side effect“. Indian Dermatology Online Journal 14, Nr. 3 (2023): 391. http://dx.doi.org/10.4103/idoj.idoj_377_22.
Der volle Inhalt der QuelleLima, Gian, Adriana Kahn, Shashank Sama und Jacqueline Savage. „Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab“. Case Reports in Oncological Medicine 2019 (04.11.2019): 1–2. http://dx.doi.org/10.1155/2019/7183747.
Der volle Inhalt der QuelleKim, Won Myung, Mun Su Park, Dong Hyun Seo, Jung Yun Lee und Jung Yoon Pyo. „Immune-related Adverse Effect after BNT162b2 Vaccination with Parallel Immune Checkpoint Inhibitor Therapy: A Case Report“. Korean Journal of Medicine 98, Nr. 2 (01.04.2023): 93–97. http://dx.doi.org/10.3904/kjm.2023.98.2.93.
Der volle Inhalt der QuelleBrinzevich, Daria, Virginia Falvello, Michael D. Green und Alex Bryant. „Impact of commonly prescribed medications on immune-related adverse events.“ Journal of Clinical Oncology 42, Nr. 16_suppl (01.06.2024): e14704-e14704. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e14704.
Der volle Inhalt der QuelleOu, Qiyun, Yunfang Yu, Haitao Zhong, Anlin Li, Yongjian Chen, HaiYu Zhou, Shaopeng Zheng, Luyu Huang und Herui Yao. „Association of immune-related adverse events with immune checkpoint inhibitor efficacy in pancancer.“ Journal of Clinical Oncology 37, Nr. 15_suppl (20.05.2019): e14087-e14087. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14087.
Der volle Inhalt der QuelleHamatake, Kiyonori, und Kazuaki Kojima. „Initiatives for immune-related adverse events by the outpatient pharmacist clinic“. Trends in Immunotherapy 6, Nr. 1 (10.01.2022): 3. http://dx.doi.org/10.24294/ti.v6.i1.1385.
Der volle Inhalt der QuelleSakai, Miho, Yuki Haga, Michiyo Kambe, Koji Nishimura, Ayako Shingyouchi, Tatsuo Miyamura, Kenji Ito et al. „A case of immune-related adverse effect diffuse gastritis induced by nivolumab“. Progress of Digestive Endoscopy 98, Nr. 1 (25.06.2021): 91–92. http://dx.doi.org/10.11641/pde.98.1_91.
Der volle Inhalt der QuelleMargiotta, Philip, Mario Caldararo, Daniel Altman, Sheel A. Patel, Sharon Li, Sean Clark-Garvey, Reetu Mukherji et al. „Effect of pretreatment steroids on the development of immune related adverse events.“ Journal of Clinical Oncology 36, Nr. 15_suppl (20.05.2018): e15095-e15095. http://dx.doi.org/10.1200/jco.2018.36.15_suppl.e15095.
Der volle Inhalt der QuelleGleeson, Ferga C., Katie A. Dunleavy, Michael J. Levy, Ryan M. Carr, Mindy L. Hartgers, Lisa A. Kottschade, Robert R. McWilliams, Wen Wee Ma, Yogish C. Kudva und Aoife M. Egan. „Incidence and Effect Duration of Immune Checkpoint Inhibitor-Related Pancreas Adverse Events“. Pancreas 53, Nr. 7 (August 2024): e627-e629. http://dx.doi.org/10.1097/mpa.0000000000002337.
Der volle Inhalt der QuelleElsayed, Manar, und Carrie Ye. „Osteoporotic fractures: an unrecognized adverse event of immune checkpoint inhibitors?“ Journal for ImmunoTherapy of Cancer 12, Nr. 7 (Juli 2024): e009309. http://dx.doi.org/10.1136/jitc-2024-009309.
Der volle Inhalt der QuelleEl Bitar, Sandy, Chanudi Weerasinghe, Elie El-Charabaty und Marcel Odaimi. „Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy“. Case Reports in Oncological Medicine 2018 (2018): 1–3. http://dx.doi.org/10.1155/2018/8408015.
Der volle Inhalt der QuelleOsataphan, Soravis, Yu Jen Jan, Katherine A. Stafford und Prudence B. Lam. „Effect of excess weight on immune-related adverse events from immune checkpoint inhibitor in lung cancer.“ Journal of Clinical Oncology 39, Nr. 15_suppl (20.05.2021): e21183-e21183. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e21183.
Der volle Inhalt der QuelleRathmann, Joerg, James J. Vredenburgh, Racha Demesropian, Dorothy Wakefield, Kendra Williams, Archana Purushothaman, Jessica Bello und Latha Dulipsingh. „Cancer-immune checkpoint inhibition and autoimmune-related adverse events.“ Journal of Clinical Oncology 37, Nr. 8_suppl (10.03.2019): 107. http://dx.doi.org/10.1200/jco.2019.37.8_suppl.107.
Der volle Inhalt der QuelleHunting, John, Eric Olson, Andrew Thomas Faucheux, Catherine A. Elko, Mary-Peyton Knapp, Sarah Price, Stephanie Brinton und Thomas William Lycan. „Effects of pre-treatment on odds of immune-related adverse events.“ Journal of Clinical Oncology 42, Nr. 16_suppl (01.06.2024): 2540. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.2540.
Der volle Inhalt der QuelleLiu, Mingyue, Xu Wang, Peng Zhang, Juanjuan Su, Xuexiang Du, Yan Zhang, Yang Liu und Pan Zheng. „813 CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect“. Journal for ImmunoTherapy of Cancer 9, Suppl 2 (November 2021): A849. http://dx.doi.org/10.1136/jitc-2021-sitc2021.813.
Der volle Inhalt der QuelleGleeson, Ferga C., Lisa Kottschade, Katie A. Dunleavy, Ryan M. Carr, Mindy Hartgers, Michael J. Levy, Wen Wee Ma, Robert McWilliams und Aoife Egan. „Tu1420 INCIDENCE AND EFFECT DURATION OF IMMUNE CHECKPOINT INHIBITOR RELATED PANCREAS ADVERSE EVENTS“. Gastroenterology 164, Nr. 6 (Mai 2023): S—1049. http://dx.doi.org/10.1016/s0016-5085(23)03438-8.
Der volle Inhalt der QuelleCautha, Sandhya, Kevin R. Jain, Pravash Budhathoki, Tobechukwu Joseph Okobi, Tanushree Bhatt, Valentina Moirangthem, Sorab Gupta, Thanh-Ha T. Luong und Ahmad Hanif. „The study of immune-related adverse events in a community-based centre.“ Journal of Clinical Oncology 41, Nr. 16_suppl (01.06.2023): 2642. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.2642.
Der volle Inhalt der QuelleZyablova, E. I., L. N. Nefedova und V. A. Porkhanov. „Radiological Imaging of Adverse Events to Immunotherapy“. Journal of oncology: diagnostic radiology and radiotherapy 3, Nr. 3 (30.09.2020): 44–53. http://dx.doi.org/10.37174/2587-7593-2020-3-3-44-53.
Der volle Inhalt der QuelleFragulidis, Georgios, Eirini Pantiora, Vasiliki Michalaki, Elissaios Kontis, Elias Primetis, Antonios Vezakis und Andreas Polydorou. „Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient“. Journal of Oncology Pharmacy Practice 25, Nr. 2 (25.10.2017): 487–91. http://dx.doi.org/10.1177/1078155217738325.
Der volle Inhalt der QuelleRai, Manoj P., Prabhjot Singh Bedi, Rohanlal Vishwanth, Fawzi Abu Rous, Shiva Shrotriya und Prajwal Dhakal. „Immune-related adverse events in melanoma: A nationwide analysis 2016.“ Journal of Clinical Oncology 37, Nr. 15_suppl (20.05.2019): e18253-e18253. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e18253.
Der volle Inhalt der QuelleGandhi, Shipra, Manu Pandey, Nischala Ammannagari, Chong Wang, Mark J. Bucsek, Lamya Hamad, Elizabeth Repasky und Marc S. Ernstoff. „Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors“. Immunotherapy 12, Nr. 2 (Februar 2020): 141–49. http://dx.doi.org/10.2217/imt-2019-0064.
Der volle Inhalt der QuelleKulkarni, Ajinkya, Mrunal Kulkarni, Vinay Edlukudige Keshava, Rithikaa Ellangovan und Rajesh Thirumaran. „Awareness of immune-related adverse events among medical residents in a community hospital.“ Journal of Clinical Oncology 38, Nr. 15_suppl (20.05.2020): e15154-e15154. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e15154.
Der volle Inhalt der QuelleLuo, Jia, Jason Beattie, Paige Fuentes, Hira Rizvi, Jacklynn V. Egger, Jeffrey Kern, Donald Y. M. Leung et al. „Beyond steroids: Immunosuppressants in steroid-refractory/resistant immune related adverse events.“ Journal of Clinical Oncology 39, Nr. 15_suppl (20.05.2021): 9092. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.9092.
Der volle Inhalt der QuelleShalata, Walid, Sarah Weissmann, Sapir Itzhaki Gabay, Kim Sheva, Omar Abu Saleh, Ashraf Abu Jama, Alexander Yakobson und Keren Rouvinov. „A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors“. Cancers 14, Nr. 21 (05.11.2022): 5451. http://dx.doi.org/10.3390/cancers14215451.
Der volle Inhalt der QuelleKhalid, Ahmed Bilal, Shadia Ibrahim Jalal und Greg Andrew Durm. „Physician awareness of immune-related adverse events from checkpoint inhibitors.“ Journal of Clinical Oncology 40, Nr. 16_suppl (01.06.2022): 6571. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.6571.
Der volle Inhalt der QuelleKhalid, Ahmed Bilal, Shadia Ibrahim Jalal und Greg Andrew Durm. „Physician awareness of immune-related adverse events from checkpoint inhibitors.“ Journal of Clinical Oncology 40, Nr. 16_suppl (01.06.2022): 6571. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.6571.
Der volle Inhalt der QuelleJiang, Ning, Yue Yu, Dawei Wu, Shuhang Wang, Peiwen Ma, Huilei Miao, Yu Tang und Ning Li. „Association between germ-line HLA and immune-related adverse events.“ Journal of Clinical Oncology 40, Nr. 16_suppl (01.06.2022): 2658. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.2658.
Der volle Inhalt der QuelleSoman, Biji, Maria Cecilia Dias, Syed Azhar J. Rizvi und Attila Kardos. „Myasthenia gravis, myositis and myocarditis: a fatal triad of immune-related adverse effect of immune checkpoint inhibitor treatment“. BMJ Case Reports 15, Nr. 12 (Dezember 2022): e251966. http://dx.doi.org/10.1136/bcr-2022-251966.
Der volle Inhalt der QuelleInagaki, Yuichiro, Hirofumi Yokota, Yuki Takeuchi, Hitomi Sawa, Takashi Seki, Hidetoshi Akita, Mamiko Takeuchi et al. „The therapeutic effect and immune-related adverse event of nivolmab in Anjo Kosei Hospital“. Annals of Oncology 30 (Oktober 2019): vi135. http://dx.doi.org/10.1093/annonc/mdz343.079.
Der volle Inhalt der QuelleNakai, Masahiro, Yoshiro Kai, Kentaro Suzuki, Masayuki Matsuda, Shoma Kikukawa, Hiroyuki Masuda, Masahiro Soga et al. „A case of perforated immune-related colitis complicated by cytomegalovirus infection during treatment of immune-related adverse effect in lung cancer immunotherapy“. Respiratory Medicine Case Reports 41 (2023): 101794. http://dx.doi.org/10.1016/j.rmcr.2022.101794.
Der volle Inhalt der QuelleRahman, Md Mominur, Tapan Behl, Md Rezaul Islam, Md Noor Alam, Md Mohaimenul Islam, Ali Albarrati, Mohammed Albratty, Abdulkarim M. Meraya und Simona Gabriela Bungau. „Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer“. Molecules 27, Nr. 12 (13.06.2022): 3798. http://dx.doi.org/10.3390/molecules27123798.
Der volle Inhalt der QuelleChang, Michael, Nira A. Krasnow, Amy E. Blum, Vartan Pahalyants, William S. Murphy, Jaewon Yoon, Kerry Lynn Reynolds, Leah L. Thompson und Steven T. Chen. „Relationship between insurance status and diagnosis of cutaneous immune-related adverse events.“ Journal of Clinical Oncology 39, Nr. 15_suppl (20.05.2021): e18535-e18535. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e18535.
Der volle Inhalt der QuelleWang, Jun, Xinyue Han, Yingcui Chen, Hong Xie, Yuekai Zhang, Yu Cui und Yaping Guan. „Organ-specific immune-related adverse events and survival in patients with cancer with immune checkpoint inhibitors.“ Journal of Clinical Oncology 42, Nr. 16_suppl (01.06.2024): 12124. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.12124.
Der volle Inhalt der QuelleReid, Pankti, Daniel Olson und Thomas Gajewski. „Assessing the effect of immunosuppressive agents for immune-related adverse event management on tumor response.“ Journal of Clinical Oncology 38, Nr. 15_suppl (20.05.2020): 3066. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3066.
Der volle Inhalt der QuelleKaszycki, Margaret A., und Jonathan Leventhal. „Review of Immune Checkpoint Inhibitors and Radiotherapy Related Skin Toxicities“. Journal of Dermatology and Skin Science 3, Nr. 3 (20.10.2021): 10–19. http://dx.doi.org/10.29245/2767-5092/2021/3.1140.
Der volle Inhalt der QuelleWanchoo, Rimda, Sabine Karam, Nupur N. Uppal, Valerie S. Barta, Gilbert Deray, Craig Devoe, Vincent Launay-Vacher und Kenar D. Jhaveri. „Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review“. American Journal of Nephrology 45, Nr. 2 (2017): 160–69. http://dx.doi.org/10.1159/000455014.
Der volle Inhalt der QuelleJamal, Shahin, Marie Hudson, Aurore Fifi-Mah und Carrie Ye. „Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist“. Journal of Rheumatology 47, Nr. 2 (15.07.2019): 166–75. http://dx.doi.org/10.3899/jrheum.190084.
Der volle Inhalt der QuelleNardi Agmon, Inbar, Osnat Itzhaki Ben Zadok und Ran Kornowski. „The Potential Cardiotoxicity of Immune Checkpoint Inhibitors“. Journal of Clinical Medicine 11, Nr. 3 (07.02.2022): 865. http://dx.doi.org/10.3390/jcm11030865.
Der volle Inhalt der QuelleShivaji, Uday N., Louisa Jeffery, Xianyong Gui, Samuel C. L. Smith, Omer F. Ahmad, Ayesha Akbar, Subrata Ghosh und Marietta Iacucci. „Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management“. Therapeutic Advances in Gastroenterology 12 (Januar 2019): 175628481988419. http://dx.doi.org/10.1177/1756284819884196.
Der volle Inhalt der QuelleTanimura, Keiko, Tadaaki Yamada, Yusuke Chihara, Yutaka Kubota, Shinsuke Shiotsu, Takayuki Takeda, Takahiro Yamada, Osamu Hiranuma, Junji Uchino und Koichi Takayama. „The Impact of Immune-related Adverse Events on the Effect of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer“. Haigan 59, Nr. 2 (20.04.2019): 128–36. http://dx.doi.org/10.2482/haigan.59.128.
Der volle Inhalt der QuelleAbdel-Wahab, Noha, Teresa Kus, Salah-Eddine Bentebibel, Jennifer Leigh McQuade, Isabella Claudia Glitza, Rodabe Navroze Amaria, Sapna Pradyuman Patel et al. „Immune-related adverse events and symptom burden in patients with melanoma receiving adjuvant immune checkpoint inhibitor.“ Journal of Clinical Oncology 40, Nr. 16_suppl (01.06.2022): TPS12147. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.tps12147.
Der volle Inhalt der QuelleSharma, Nitika, Prashanti Atluri, Chipman Robert Geoffrey Stroud, Paul R. Walker, Sulochana Devi Cherukuri, Cynthia R. Cherry, Paul Gibbs, Teresa Parent und Jessica Hardin. „Immune related adverse events (irAEs): A unique profile based on tumor type.“ Journal of Clinical Oncology 35, Nr. 15_suppl (20.05.2017): e14606-e14606. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e14606.
Der volle Inhalt der QuelleNasca, Vincenzo, Francesco Barretta, Francesca Corti, Sara Lonardi, Monica Niger, Maria Elena Elez, Marwan Fakih et al. „Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer“. Journal for ImmunoTherapy of Cancer 11, Nr. 1 (Januar 2023): e005493. http://dx.doi.org/10.1136/jitc-2022-005493.
Der volle Inhalt der QuelleMooradian, Meghan, Justine Vanessa Cohen, Anita Giobbie-Hurder, Riley Fadden, Krista M. Rubin, Keith Flaherty, Don P. Lawrence und Ryan J. Sullivan. „Inflammatory arthritis: An under-recognized immune-relate adverse effect.“ Journal of Clinical Oncology 35, Nr. 15_suppl (20.05.2017): e14565-e14565. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e14565.
Der volle Inhalt der QuelleOren, Ohad, und Julian R. Molina. „The effect of cardiovascular disease on the association between immune-related adverse events and overall survival.“ Journal of Clinical Oncology 38, Nr. 15_suppl (20.05.2020): 7059. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.7059.
Der volle Inhalt der QuelleDe Bock, Marlies, Eva Hulstaert, Vibeke Kruse und Lieve Brochez. „Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review“. Case Reports in Dermatology 10, Nr. 2 (09.08.2018): 190–97. http://dx.doi.org/10.1159/000491572.
Der volle Inhalt der QuelleHigashiyama, Ryoko Inaba, Hidehito Horinouchi, Katsutoshi Sekine, Yuji Matsumoto, Shuji Murakami, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Noboru Yamamoto und Yuichiro Ohe. „Efficacy of nivolumab in patients treated by corticosteroid due to immune-related adverse events.“ Journal of Clinical Oncology 36, Nr. 5_suppl (10.02.2018): 163. http://dx.doi.org/10.1200/jco.2018.36.5_suppl.163.
Der volle Inhalt der Quelle